Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday

Unicycive Therapeutics (NASDAQ:UNCY) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $0.66 on Thursday. The stock has a 50 day simple moving average of $0.59 and a 200 day simple moving average of $0.55. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.60. The firm has a market capitalization of $68.91 million, a PE ratio of -0.68 and a beta of 2.26.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on UNCY shares. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Unicycive Therapeutics in a research report on Wednesday, January 29th. Benchmark reiterated a “speculative buy” rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, November 22nd.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.